Phase 1 N=46 Comparison of Intravenous Adenosine Infusion With Regadenoson Bolus for Inducing Maximal Coronary Hyperemia
Coronary Artery Disease
Primary: Difference in FFR Between IV Adenosine and IV Regadenoson — 0.84; 0.84 ratio (Pd/Pa)
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 1 N=18 To Evaluate the Food Effect on Relative Bioavailability of RP6530 in Healthy Volunteers
Healthy
Primary: Pharmacokinetic Parameters (Area Under the Plasma Concentration Versus Time Curve (AUC)) — 5277.01; 6726.99 nanogram*hour per millilitre (ng*h/mL) — p=0.0002
Phase 1 N=44 Safety and Tolerability of Odanacatib (0822-059)
Osteoporosis
Primary: Weighted Average Inhibition (WAI) of Urine Aminoterminal Crosslinked Telopeptide of Type I Collagen (u-NTx/Cr) After Administration of Odanacatib 50 mg or Placebo Qw for…
Phase 1 N=27 Effect of Calcium 500 mg and Vitamin D3 1000 IU Chewable Tablet on Intestinal Calcium Absorption
Healthy Volunteers
Primary: PTH AUC(0-6): Area Under the Serum Concentration-Time Curve From Time 0 to 6 Hours for Parathyroid Hormone — 215; 157 hour*picogram per milliliter (hr*pg/mL)
Phase 1 N=30 A Study to Assess the Bioavailability and to Compare the Pharmacokinetics of AZD7594 Inhaled Via Monodose Inhaler and Multiple-dose Dry Powder Inhalers (DPI) or Pressurized Metered-dose Inhaler (pMDI) in Healthy Male Subjects
Asthma · Chronic Obstructive Pulmonary Disease (COPD)
Primary: Pharmacokinetics (PK) of AZD7594 Delivered by Monodose Inhaler and Multiple-dose DPI or pMDI in Terms of Pulmonary Bioavailability After Inhalation (Fpulmonary) — 27.49…
Phase 1 N=15 Study of Dalotuzumab (MK-0646) in Adults With Solid Tumors (MK-0646-009)
Neoplasm
Primary: Number of Participants Who Experienced a Dose-limiting Toxicity (DLT) — 0; 0; 0 Participants
Phase 1 N=879 Clinical Efficacy Study of Salmeterol Xinafoate/Fluticasone Propionate in Asthma
Asthma
Primary: Area Under the Serial FEV1-time Curve (AUC 0-12h) — 29.610; 30.151; 27.270 Liters — p=<0.05
Phase 1 N=8 A Study to Measure Baricitinib (LY3009104) Absorption in Healthy Participants
Healthy Volunteers
Primary: Pharmacokinetics: Area Under the Concentration Versus Time Curve From Zero to Infinity (AUC[0-∞]) of Baricitinib Following Both the Oral and the IV Dose — 216; 0.274…
Phase 1 N=40 Safety and Efficacy of Topical Tacrolimus 0.05% in the Treatment of Ocular Graft-Versus-Host Disease
Ocular GVHD
Primary: Ocular Burning Sensation, Ocular Discharge, Ocular Redness, Ocular Itching, Foreign Body Sensation — 3.50; 2.23; 0.16; 0.26 units on a scale — p=0.0019
Phase 1 N=678 Safety and Immunogenicity of a Group B Streptococcus Vaccine in Healthy Women
Group B Streptococcus
Primary: Percentage of Subjects Achieving Specific Thresholds of Antibody Concentrations for Subjects in Enrollment Group 1 — 38; 30; 30; 29 percentage of subjects
Phase 1 N=23 Amendment of rTSST-1 Variant Vaccine Phase 1 Clinical Trial
Toxic-Shock Syndrome · Sepsis
Primary: Number of Participants With Adverse Events as a Measure of Safety — 7; 1; 1; 0 participants
Phase 1 N=30 A Study to Assess Bioavailability and Pharmacokinetics of CAT- 354
Asthma · Healthy
Primary: Absolute Bioavailability of CAT-354 After Subcutaneous Dose — 62.1; 60.1 percent bioavailability
Phase 1 N=74 A Phase 1 Study to Assess the Safety, Tolerability, and Pharmacokinetics of TAK-079 in Healthy Participants
Autoimmune Disease
Primary: Number of Participants Who Experience at Least 1 Treatment-emergent Adverse Event (TEAE) and Serious Adverse Event (SAE) — 6; 3; 2; 1 participants
Phase 1 N=31 A Study of the Effect of MK-8457 on Blood Pressure in Hypertensive Participants (MK-8457-004-AM1)
Hypertension
Primary: Change From Baseline to Day 10 in 24-hour Mean Ambulatory Systolic Blood Pressure (SBP) — -0.47; -2.49 mmHg
Phase 1 N=48 Two Way Bioequivalence Study Under Fed Conditions
Healthy
Primary: Area Under Plasma Concentration — 213.7; 225.9 ng*hr/ml — p=0.05